Multiple Sclerosis Drug Market

Analysis by Drug (Immunomodulators, Immunosuppressants, Interferons, and Others); by Medication Type (Oral and Injection); by Type (Clinically Isolated Syndrome, Relapse-Remitting MS, Primary Progressive MS, and Secondary Progressive MS); by Treatment (Medications, Stem Cell Therapy, Physical Therapy, and Plasma Exchange); and by End User (Hospitals, Specialty, Clinics, Homecare, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

Buy Now
Report ID: 1986 | Published On: Feb 14, 2023
Request Free Sample Copy

Global Multiple Sclerosis Drug Market Size, Forecast, and Trend Highlights Over 2023 - 2033

The global multiple sclerosis drug market is estimated to garner a revenue of ~USD 28,000 Million by the end of 2033 by growing at a CAGR of ~4% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 23,000 Million in the year 2022. The market growth is primarily driven by the rising number of new drug candidates for multiple sclerosis being developed and pre-clinical trials are ongoing. Worldwide, nearly 3 million people are living with multiple sclerosis. Therefore, an increase in the number of sclerosis patients is expected to result in a rise in the need for medications and medical care.

Global-Multiple-Sclerosis-Drug-Market-overviewGet more information on this report: Request Sample PDF

The efficacy of the medicines and surging development in the treatment of multiple sclerosis are expected to boost market growth. In June 2021, Bristol Myer Squibb released the progressive result of the early Zepsosia treatment, nearly, 80% of patients with high thalamic volume benefitted from the drug. Furthermore, proactive government efforts for multiple sclerosis patients are expected to propel the growth of the global multiple sclerosis drug market. In India, the government proposed to add multiple sclerosis in the Ayushman Bharat Scheme, a Nation Health Protection Mission, this initiative is to reduce the cost of treatment in the country. Moreover, in China as well, the government added multiple sclerosis to the list of rare diseases to improve the treatment outcomes of the patient.

Get more information on this report: Request Sample PDF

Global Multiple Sclerosis Drug Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 23,000 Million

Forecast Year Market Size (2033)

~ USD 28,000 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Global Multiple Sclerosis Drug Market: Growth Drivers and Challenges

Growth Drivers

  • Higher Number of People Suffering from Multiple Sclerosis - MS (Multiple Sclerosis) occurs at any age, the initial range is most often between the ages of 20 and 40. However, individuals of various ages are affected. The prevalence of multiple sclerosis has increased worldwide. According to the National Library of Medicine, the prevalence of sclerosis is 35.9 per 100,000 people and 2.8million people are suffering from multiple sclerosis in 2020.

  • Government Support for the Sclerosis Patient - With the rising number of sclerosis patients, the government has come forward to aid the treatment of the patients. Under the Anuyatra project launched by the Kerala government, India, the government has sanctioned nearly USD 116 thousand for the treatment of sclerosis. Moreover, in 2021, the 4 nations of the United Kingdom launched a Rare Disease Action Plan to address all rare diseases including multiple sclerosis.

  • Growing Research and Development in the Treatment of Sclerosis – Owing to the exceptional research, the development in sclerosis diagnosis, drugs, and treatment is incessantly rising. For instance, Adamas Pharmaceuticals, Inc., has announced the beginning of phase 3 of the safety and efficiency of ADS-5102 in patients with multiple sclerosis and walking impairment.

  • Rapid Growth of the Healthcare Sector - Healthcare sector was always a booming sector and it has been further loaded after the onset of COVID-19. The exigency of good healthcare facilities has aided its growth. According to the World Economic Forum, in 2021, USD 44 billion of the fund was raised for health innovation.

  • Increasing Prevalence of Multiple Sclerosis Among Women - Women are more prone to multiple sclerosis. More women are diagnosed with sclerosis than men. The ratio of men and women with multiple sclerosis is 1:4.


  • Expensive Treatment and Drugs of Multiple Sclerosis - The cost of treatment and drugs is a big hindrance to the market growth. Despite of government’s proactive actions for the progress of multiple sclerosis treatment. The high price of medicines fails to suffice the needs of the market. Depending on the patient's age and gender, the cost of an MS (Multiple Sclerosis) disease-modifying therapy ranged from USD 57,202 to USD 92,719 per year.

  • Shortage of Skilled Professionals & Lack of Healthcare Infrastructure

  • Difficulty in Developing Drugs due to Unidentified Etiology of the Disease

The multiple sclerosis drug market is segmented and analyzed for demand and supply by medication type into oral and injection. The oral segment is expected to hold the largest market size by the end of 2033, owing to its better efficacy and favorable safety profile against other available treatments. Most oral MS therapies currently on the market have been granted marketing approvals by regulatory agencies. For instance, Cipla Inc. received approval from the United States Food and Drug Administration for Tecfidera (dimethyl fumarate DR capsules), an oral drug to treat the relapsing forms of multiple sclerosis.

Global Multiple Sclerosis Drug Market Regional Synopsis

The North America multiple sclerosis drug market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. A few variables that are anticipated to drive the expansion of the market in North America include an increase in the global burden of multiple sclerosis among the population and a higher probability of women getting multiple sclerosis. In the United States, every week, around 200 new cases are added to the list of multiple sclerosis patients. Moreover, in 2019, nearly 400,000 people were affected by it. In North America, there are around 140 cases per 100,000 population and out of them, about 70% of patients are women, further, in the past 30 years, the ratio of women to men has jumped from 2:1 to 3:1. Furthermore, the development in the healthcare sector in North America is to elevate the growth of the market in the region. At the end of 2019, the total expenditure on health facilities in the U.S. was worth nearly 18% of the U.S. gross domestic product (GDP), and it is expected to total USD 6 trillion annually by 2028.


Market Segmentation

Our in-depth analysis of the global multiple sclerosis drug market includes the following segments:

        By Drug

  • Immunomodulators
  • Immunosuppressants
  • Interferons
  • Others

       By Type

  • Clinically Isolated Syndrome
  • Relapse-Remitting MS
  • Primary Progressive MS
  • Secondary Progressive MS

      By Medication Type

  • Oral
  • Injection



       By Treatment

  • Medications
  • Stem Cell Therapy
  • Physical Therapy
  • Plasma Exchange

       By End User

  • Hospitals
  • Specialty
  • Clinics
  • Homecare
  • Others

Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Global Multiple Sclerosis Drug Market

    • Biogen

      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Merck KGaA.
    • Janssen Pharmaceuticals Companies of Johnson & Johnson
    • Bristol-Myers Squibb Company
    • Cipla Inc. 

In The News

  • April 2022: IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
  • March 2022: Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the multiple sclerosis drug market?

Ans: Factors such as, higher prevalence of multiple sclerosis, advancement in research and development, higher instances of women having multiple sclerosis and government efforts for the treatment is to drive the market growth.

2) What would be the CAGR of multiple sclerosis drug market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~4% over the forecast period, i.e., 2023 – 2033.

3) What are the challenges affecting the multiple sclerosis drug market growth?

Ans: High cost of treatment of multiple sclerosis, shortage of skilled professionals and challenges to develop the drugs for the treatment are few factors which are to hamper the market growth.

4) Which region will provide more business opportunities for growth of multiple sclerosis drug market in future?

Ans: The major players in the market are Biogen, Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Merck KGaA., Janssen Pharmaceuticals Companies of Johnson & Johnson, Bristol-Myers Squibb Company, Cipla Inc., and so on…

5) Who are the major players dominating the multiple sclerosis drug market?

Ans: The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the multiple sclerosis drug market?

Ans: The market is segmented by drug, type, medication type, treatment, end user, and by region.

8) Which segment captures the largest market size in medication type in the multiple sclerosis drug market?

Ans: The oral segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample